Atsena Therapeutics announced in a press release that the FDA granted its gene therapy product candidate, ATSN-201, the regenerative medicine advanced therapy (RMAT) designation to treat X-linked ...

A new Chinese report recognized that social media smartphone application–based interventions significantly improved follow-up adherence and increased parental knowledge among families of children with ...

Pykus Therapeutics announced it has completed enrollment in its pilot study, PYK-2101-RD00, evaluating PYK-2101, a focal hydrogel retinal sealant, in patients undergoing surgery for detached retina.

A new study found that an artificial intelligence reading label system improves ophthalmologists' diagnostic accuracy for retinal diseases and could be valuable in future medical education. A new ...

Opus Genetics issued a press release today announcing the 1-month open-label phase 1/2 results from the first pediatric patients treated with its investigational gene therapy candidate, OPGx-LCA5, for ...

A study found that children with early-onset atopic dermatitis have a higher risk of developing uveitis and should be closely monitored for its onset. Taiwanese investigators found in their cohort ...

As part of its five-year strategic plan, Prevent Blindness has promoted five individuals to further the organization’s mission. Prevent Blindness has promoted five leaders to further its efforts and ...

VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME). Vantage ...

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.